Stay updated on Incyte Press Releases
Sign up to get notified when there's something new on the Incyte Press Releases page.
Latest updates to the Incyte Press Releases page
- Check6 days agoChange DetectedIncyte has updated the presentation time for an upcoming investor conference and will highlight new data, including a late-breaking oral presentation for Tafasitamab in Follicular Lymphoma, at the 2024 ASH Annual Meeting.SummaryDifference32%
- Check13 days agoChange DetectedIncyte has provided an update on its early phase MRGPRX2 and MRGPRX4 programs as of November 18, 2024, while a previous announcement regarding late-breaking data presentations at the EADV 2024 Congress has been removed.SummaryDifference21%
- Check21 days agoChange DetectedIncyte has announced its upcoming presentation at an investor conference on November 14, 2024, while a previous announcement regarding a publication related to the AGAVE-201 trial has been removed.SummaryDifference17%
- Check28 days agoChange DetectedIncyte has reported inducement grants under Nasdaq Listing Rule 5635(c)(4) on November 7, 2024, while a previous report on the promising clinical activity of their CDK2 inhibitor has been removed.SummaryDifference17%
- Check35 days agoChange DetectedIncyte has reported its 2024 third quarter financial results and will present at upcoming investor conferences, while a previous report on Retifanlimab's efficacy in SCAC has been removed.SummaryDifference100%
- Check43 days agoChange DetectedIncyte has been recognized as one of the top 5 companies on Science Magazine’s 2024 Top Employers List, while a previous announcement regarding their presentation at the ESMO Congress has been removed.SummaryDifference100%
Stay in the know with updates to Incyte Press Releases
Enter your email address, and we'll notify you when there's something new on the Incyte Press Releases page.